KRAS and Miyoshi myopathy: Moreover, PAK1/2 inhibition did not reduce RAS protein expression in AMO1 and H1112 MM cells harboring KRAS A146 mutations (Fig. S6E–G), in agreement with our above data demonstrating that A146 mutations protect RAS from LZTR1-mediated degradation regardless T148 phosphorylation status.